FCGR3A rs396991: What Your Genotype Means for Drug Response
The rs396991 variant is a common genetic change in the FCGR3A gene that alters the structure of a receptor on immune cells. This variation is studied for its potential role in influencing how effectively certain monoclonal antibody medications, such as rituximab, interact with the immune system.
What each genotype means
High affinity receptor variant
This genotype results in the expression of the high-affinity Valine (V) variant of the CD16 receptor. Research suggests this may lead to enhanced antibody-dependent cellular cytotoxicity (ADCC) and potentially improved responses to certain monoclonal antibody therapies, though clinical findings remain mixed across different conditions. Please discuss the implications of this genotype for your specific treatment plan with your clinician or pharmacist.
This genotype is less common than the FF genotype in many European populations, with the G allele frequency typically ranging between 0.35 and 0.45.
Intermediate affinity receptor variant
This genotype represents a heterozygous state, producing both the high-affinity Valine (V) and lower-affinity Phenylalanine (F) versions of the CD16 receptor. The functional impact on immune response and therapeutic efficacy is considered intermediate compared to homozygous individuals. Please consult with your healthcare provider or pharmacist to understand how this may relate to your specific medical context or medication response.
This is a common genotype observed in diverse populations, reflecting the balanced distribution of the G and T alleles in many global cohorts.
Lower affinity receptor variant
This genotype results in the expression of the lower-affinity Phenylalanine (F) variant of the CD16 receptor. Some studies suggest this may be associated with reduced efficacy for certain monoclonal antibody treatments compared to the high-affinity variant, though results are inconsistent across different diseases and therapies. You should discuss the relevance of this finding to your treatment options with your clinician or pharmacist.
This genotype is frequently observed, as the T allele (often referred to as the F allele in literature) is common across many global populations.
Understanding the rs396991 Variant
The rs396991 variant is a single nucleotide polymorphism (SNP) located within the FCGR3A gene. In genetic terms, this variant represents a change at a specific position in the DNA sequence, resulting in an amino acid substitution at position 176 (often referred to as 158 in mature protein numbering) of the encoded protein. Specifically, it involves a switch between phenylalanine (F) and valine (V). This small change is significant because it occurs in the region of the protein that binds to the Fc portion of immunoglobulin G (IgG) antibodies. Because this binding is a critical step in how the immune system recognizes and eliminates targeted cells, researchers have long investigated whether this specific genetic difference leads to measurable variations in how patients respond to antibody-based treatments.
The Role of the FCGR3A Gene
The FCGR3A gene provides instructions for creating the Fc gamma receptor IIIa protein, also known as CD16a. This receptor is primarily found on the surface of natural killer (NK) cells and certain types of macrophages. Its main function is to bind to the tail end, or Fc region, of IgG antibodies that have attached to pathogens or tumor cells. Once bound, the receptor triggers a process called antibody-dependent cellular cytotoxicity (ADCC), which allows the immune cell to destroy the target. By acting as a bridge between the antibody and the immune cell, the FCGR3A protein is essential for the mechanism of action of many modern monoclonal antibody therapies used in oncology and autoimmune diseases. Variations in this gene can theoretically change the receptor's affinity for these antibodies, potentially altering the efficiency of the immune response.
Research and Clinical Evidence
Research into rs396991 has primarily focused on its association with the efficacy of monoclonal antibody therapies like rituximab. Many studies suggest that the valine (V) allele may be associated with higher binding affinity for IgG1 compared to the phenylalanine (F) allele, potentially leading to more effective tumor cell killing in laboratory settings. In clinical cohorts, some studies have observed that patients carrying the V allele show improved response rates or longer progression-free survival when treated with rituximab for conditions like non-Hodgkin lymphoma. However, the evidence remains limited and sometimes inconsistent across different patient populations and disease types. Because of these mixed results, this variant is not currently used as a definitive clinical tool for prescribing decisions. It is important to note that drug response is complex and influenced by many factors beyond a single genetic variant.
What This Information Means for You
If you have received results regarding your rs396991 genotype, it is important to view this information as a piece of a much larger puzzle. While scientific literature explores the potential impact of this variant on drug efficacy, it is not a diagnostic test that can predict your personal outcome with certainty. Many other genetic and environmental factors contribute to how a patient responds to medication. You should never use this information to make decisions about your treatment, such as stopping or changing a prescribed medication. If you are concerned about how a specific therapy might work for you, the best course of action is to discuss your genetic profile with your clinician or a pharmacist. They can provide context based on your full medical history and the current standard of care for your specific condition.
How common is this variant?
The G allele (valine) frequency is approximately 0.35 to 0.45 across many European and Asian populations, making both the homozygous and heterozygous genotypes relatively common.
Frequently asked questions
Is rs396991 a diagnostic test for drug response?
No, rs396991 is not a diagnostic test. While it is a subject of pharmacogenomic research, it is not currently used as a standard clinical tool to predict individual patient responses to medication.
Can I change my medication based on my FCGR3A genotype?
You should never change or stop your medication based on genetic test results. Always consult with your healthcare provider or pharmacist before making any changes to your prescribed treatment plan.
Why do some studies show different results for this variant?
Genetic associations can vary due to differences in study design, the specific disease being treated, the patient population, and the complex nature of drug metabolism and immune response. These factors often lead to mixed or limited evidence.
What is the difference between the V and F alleles?
The V (valine) and F (phenylalanine) alleles represent a structural change in the FCGR3A protein. This change can affect how the receptor binds to the Fc portion of IgG antibodies, which is a key step in the function of certain therapeutic antibodies.
Sources & further reading
Educational information only, last refreshed 9/21/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs396991?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29